Office Of New Drugs Reorganization Should Better Balance Workload, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
CDER's Office of New Drugs reorganizes as rheumatology moves from analgesics to join allergy.
You may also be interested in...
Anti-Infective Product Development Is Focus Of Latest FDA Drug Review Reorg
The latest reorganization within FDA’s Office of New Drugs is aimed at strengthening the agency’s focus on emerging issues in anti-infective product development.
Anti-Infective Product Development Is Focus Of Latest FDA Drug Review Reorg
The latest reorganization within FDA’s Office of New Drugs is aimed at strengthening the agency’s focus on emerging issues in anti-infective product development.
Ampligen Will Be Early Test Of FDA Consolidation Of Chronic Fatigue Drug Reviews
FDA’s decision to consolidate oversight for chronic fatigue syndrome treatments in the Division of Pulmonary, Allergy and Rheumatology Products will face an early test with Hemispherx Biopharma Inc.’s expected submission of an amended NDA for its investigational agent Ampligen in the third quarter.